A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity, sponsored by Novo Nordisk A/S. Active, not recruiting at 256 sites in 23 countries. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.
Among the 36 studies testing cagrilintide in Obesity, this one has the largest planned enrollment, is the only one that started in 2022, is one of 15 in phase 3, reaches primary completion later than 0 of the 14 other live ones, and was the 10th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Greece, Hungary and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 16 more countries
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18–64
Novo Nordisk A/S · Sites in Germany
Ages 18–64
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, cagrilintide is the treatment under test here. Read study by study →
36 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,400 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 154 across the 36 interventional studies. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 36 have an industry lead sponsor. The 1 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
207 studies in Obesity by Novo Nordisk A/S: 48 open now, 66 under way, 26 of them phase 3. Of 138 finished, 39 (28%) have results posted.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 6th largest by planned enrollment of the 166 interventional ones that give a count, is one of 13 that started in 2022, is one of 62 in phase 3, reaches primary completion later than 1 of the 65 other live ones, and was the 94th registered.
Novo Nordisk A/S’s Obesity studies by the year they started, since 2007.
8 of the studies testing cagrilintide in Obesity that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07557953Novo Nordisk A/SA Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity | 2027-04-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 36 studies testing cagrilintide in Obesity, from their registry updates:
Among Novo Nordisk A/S’s 207 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSema, cagrilintide,semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. They will take one injection once a week. The study medicine is injected briefly with a thin needle, typically in the stomach, thighs or upper arms.
Extension study: After the main study, not all participants will continue in the extension study. The study staff will tell the participant if they will continue or not into the extension study. In the extension study we will look at what happens to the participant's body weight and diseases related to excess body weight after the participant stops taking the study medicine. The main study will last for about 1½ years and the extension study will last for another 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Glycaemia related: a) (HbA1c) greater than or equal to 6.5 percent (48 millimoles per mole [mmol/mol]) as measured by the central laboratory at screening b) History of type 1 or type 2 diabetes mellitus
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive cagrilintide and semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks in the main phase. Participants randomised to this arm will be included in the extension phase for 97 weeks.
Drug: Cagrilintide · Drug: Semaglutide
Participants will receive cagrilintide s.c. and placebo matching to semaglutide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.
Drug: Cagrilintide · Drug: Placebo semaglutide
Participants will receive semaglutide s.c.and placebo matched to cagrilintide once-weekly after a dose escalation period of 16 weeks during the maintenance period for 52 weeks.
Drug: Semaglutide · Drug: Placebo cagrilintide
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 68 weeks. Participants randomised to this arm will be included in the extension phase for 97 weeks.
Drug: Placebo cagrilintide · Drug: Placebo semaglutide
Cagrilintide will be administered subcutaneously.
Participants will recieve semaglutide subcutaneously.
Participants will receive placebo matched to cagrilintide.
Participants will receive placebo matched to semaglutide.
CagriSema versus placebo: Relative change in body weight
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of greater than or equal to (>=) 5% weight reduction
Measured as count of participants
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of >= 20% weight reduction
Measured as count of participant
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of >= 25% weight reduction
Measured as count of participant
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of >= 30% weight reduction
Measured as count of participant
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus cagrilintide and CagriSema versus semaglutide: Relative change in body weight
Measured as percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Relative change in body weight
Measured as percentage (%)
Time frame: From baseline (week 0) to week 8
CagriSema versus placebo: Relative change in body weight
Measured as percentage (%)
Time frame: From baseline (week 0) to week 20
CagriSema versus placebo: Change in waist circumference
Measured in centimeters (cm)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in systolic blood pressure (SBP)
Measured in millimeters of mercury (mmHg)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in SF-v2 Health Survey Acute (SF-36 v2 Acute) Physical Functioning Score
Measured as score points. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo, semaglutide and cagrilintide: Change in body weight
Measured in kilograms (kg)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo, semalutide and cagrilintide: Change in body mass index (BMI)
Measured in kilogram per square meter (kg/m\^2)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo, semaglutide and cagrilintide: Improvement in weight category
Measured as count of participants. The categories are: BMI, underweight less than (\<) 18.5, normal weight 18.5 to \<25, overweight 25.0 to \<30, obesity class I 30 to \< 35, obesity class II 35 to \< 40, obesity class III \>40.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in Glycated Haemoglobin (HbA1c)
Measured as percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in HbA1c
Measured as millimoles per mole (mmol/mol).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in Fasting Plasma Glucose (FPG) (mmol/L).
Measured as millimoles per liter (mmol/L).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in FPG (mg/dL)
Measured as milligrams per deciliter (mg/dL).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in fasting serum insulin
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in Diastolic Blood Pressure (DBP)
Measured in mmHg
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in total cholesterol
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in High-density lipoprotein (HDL) cholesterol
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in Low-density lipoprotein (LDL) cholesterol
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in Very low-density lipoprotein (VLDL) cholesterol
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in Triglycerides
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Ratio to baseline in Free fatty acids
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Change in waist circumference
Measured in centimeters (cm)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Change in SBP
Measured in mmHg
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in total cholesterol
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in HDL
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in LDL
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in VLDL
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Triglycerides
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus semaglutide and cagrilintide: Ratio to baseline in Free fatty acids
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Relative change in body weight (Measured in kilograms (kg))
Measured in kilograms (kg).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Relative change in body weight (Measured in percentage (%))
Measured in percentage (%).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Absolute change in body weight (Measured in kilograms (kg))
Measured in kilograms (kg).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Absolute change in body weight (Measured in percentage (%))
Measured in percentage (%).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as kilograms (kg))
Measured as kilograms (kg)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a absolute to total body mass (Measured as percentage (%))
Measured as percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as kilograms (kg))
Measured as kilograms (kg)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in total fat mass by Dual energy X-ray absorption (DXA)a relative to total body mass (Measured as percentage (%))
Measured as percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as percentage (%))
Measured as percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to baseline of fat mass in visceral fat mass region (Measured as %-points)
Measured as %-points
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as percentage (%))
Measured as percentage (%).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in visceral fat mass by DXA, relative to total amount of fat mass in visceral fat mass region (Measured as %-points)
Measured as %-points
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in kilograms (kg))
Measured in kilograms (kg)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in lean body mass by DXA absolute to total body mass (Measured in percentage (%))
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in kilograms (kg))
Measured in kilograms (kg)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in lean body mass by DXA relative to total body mass (Measured in percentage (%))
Measured in percentage (%)
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of at least 14.6- point increase (yes/no) in IWQOL-Lite-CT Physical Function score
Measured as count of participants. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Achievement of at least 3.7-point increase (yes/no) in SF-36v2 Physical Functioning score
Measured as count of participants. The SF-36v2 Acute measures Health-Related Quality of Life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2. Acute scores are norm-based scores, i.e. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in IWQOL-Lite-CT - Physical Function Score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in IWQOL-Lite-CT - Psychosocial Score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo: Change in IWQOL-Lite-CT - Total Score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in Control of Eating (COEQ): Craving Control Score
Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in COEQ: Craving for Savoury food score
Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in COEQ: Hunger score
Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in COEQ: Craving for Sweets Score
Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in COEQ: Positive Mood score
Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Time frame: From baseline (week 0) to end of treatment (week 68)
Change in COEQ: Satiety score
Measured as score points. CoEQ is a 19-item multidimensional patient-reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), and craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10).
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Change in IWQOL-Lite-CT Physical Function score
Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patients' physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo for subgroup with baseline PGI-S assessment 'Poor' : Achievement of at least 14.6-point increase (yes/no) in IWQOL-Lite-CT Physical Function score
Measured as count of participants.
Time frame: From baseline (week 0) to end of treatment (week 68)
CagriSema versus placebo, semalutide and cagrilintide: Ratio to baseline C-reactive protein (CRP)
Measured as ratio
Time frame: From baseline (week 0) to end of treatment (week 68)
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as count of events
Time frame: From baseline (week 0) to end of study-main part (week 75)
Number of Treatment Emergent Serious adverse events (TESAEs)
Measured as count of events.
Time frame: From baseline (week 0) to end of study-main part (week 75)
Showing the first 100 of 256 sites across 23 countries. Choose a country and city above to see the rest.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Nov 2022 to primary completion in Oct 2024, 23 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 23 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cagrilintide